Amyloidosis is rare, but known cause of heart failure, cardiomyopathy, coronary artery disease, disorders of cardiac conduction system and valvular damage. Disease often remains undetected until it reaches an advanced stage. Currently, we distinguish several types of amyloidosis. Cardiac amyloidosis may be caused by cancer, chronic inflammation, genetic factors and by aging related processes.
INTRODUCTION
. In normal circumstances, such substances are degraded intracellularly in proteasomes, or macrophages. In amyloidosis, there is failure in "control and quality" mechanisms, leading to extracellular accumulation of the amyloid [2, 3] . Amyloidosis usually develops in patients with an enzymatic disorder that impairs the organism's ability to degrade amyloid. Thus, the organism's ability to eliminate amyloid is negligible. Genetically-based structural abnormalities in amyloid molecules ensure their resistance to degradation by macrophages. It should be noted that mutant forms of apolipoprotein A1, fibrinogen and gelsolin are also precursor molecules for amyloid deposits. However, their occurrence in the heart is sporadic.
CARDIAC AMYLOIDOSIS TYPES
accumulation. For example, Vλ VI light chains often accumulate in the kidneys while Vλ II accumulate primarily in the heart [10] . Genetic analysis of plasma cells producing amyloidogenic immunoglobulins revealed that amyloid tissue tropism is associated with a gene in the variable segment of the light chain [11] . cardiomyopathy, and occasionally arrhythmia [5] . The most common mutation is Val30Met, which accounts for over 60% of the cases [12] . In comparison to AL amyloidosis, ATTR is a slowly progressing disease, with most patients surviving for many years after the first onset of symptoms [13] .
Transthyretin-related amyloidosis
Non-hereditary form (wild-type or senile form) of amyloidosis is related to the decomposition of the normal TTR molecule.
The amyloidogenic transthyretin particles accumulate mainly in the heart. This form is rarely clinically diagnosed. Most importantly, there has been increasing evidence that this type of cardiac amyloidosis is underdiagnosed since it affects up to 25% of the senile population [6] . This form is found mostly in the male population [14] . Increased life expectancy and advancement in diagnostic methods may result in new challenges when treating this population.
Given that the heart is the only clinically affected organ in this type of amyloidosis, perimalleolar edema or dyspnea are usually the first signs of disease. These signs are automatically associated Pathophysiological mechanisms of cardiac damage according to different types of amyloidosis (modified according to [7] ).
with congestive heart failure. Interestingly, many patients with this form of amyloidosis have reported tingling and hypoesthesia in the hands. In these patients, the carpal tunnel syndrome induced by amyloid deposits can manifest 3-5 years prior to the onset of cardiac symptoms [15] .
Secondary serum amyloid A amyloidosis
Serum amyloid A (SAA) is the common name for a group of proteins coded by several genes [2] . In this type of amyloidosis, heart deposits are exceedingly rare and manifest with bland symptoms. Secondary SAA amyloidosis is a reaction to chronic inflammation. It occurs in 20% of patients with rheumatic arthritis. The incidence of amyloidosis in these patients is decreasing with better management of chronic inflammation. The heart is affected in 2% of the cases [16] .
Isolated atrial amyloidosis
Isolated atrial amyloidosis is an example of amyloidosis local and specific to the myocardium. It is a disease of the senile population with a female predominance [14] . Amyloid forms from the atrial natriuretic peptide (ANP) and deposits mainly in the atria.
There was no evidence that conditions causing increase in ANP production would support the development of isolated atrial amyloidosis. This structural abnormality was always diagnosed post mortem. The affected portion of the atrium showed a higher risk of perforation. The prevalence of isolated atrial amyloidosis increases with age, reaching up to 95% in 81 to 90-year--old patients [17, 18] . Despite its high prevalence, isolated atrial amyloidosis is considered to be of no clinical relevance to heart failure [19] . Nevertheless, there are studies that predict a role of isolated atrial amyloidosis in the development of disorders of the conduction system and atrial fibrillation in older population [1, 18] . A recent study involving a group of middle-aged patients with mean age of 40 years with diagnosis of congestive heart failure showed the presence of amyloid deposits in 91.6% of cases, where 93.9% of them were positive for ANP [20] . This demonstrates the need to monitor these patients due to an increased risk of progressive heart amyloidosis.
AL AMYLOIDOSIS AND CARDIOVASCULAR DAMAGE
AL amyloidosis is a monoclonal gamapathy frequently resulting from a myeloma, Waldenström's macroglobulinemia or a monoclonal gamopathy of unknown significance. Between 10% to 20% of myeloma patients develop AL amyloidosis [21, 22] . Monoclonal plasma cells which produce amyloidogenic light chains are located in the bone marrow, or the spleen. Patients with primary AL amyloidosis have amyloid deposits in the myocardium that lead to the development of rapidly progressive heart failure/ infiltrative cardiomyopathy, ventricular tachyarrhythmia and more than 50% mortality rate within one year after the onset of symptoms [23] . Primary AL amyloidosis typically affects older adults with median age at diagnosis 67 years. Approximately fifty percent patients with cardiac AL amyloidosis have renal involvement, about 16% have liver involvement, and about 10% have neurological involvement [9] .
The pathogenesis of AL amyloid cardiomyopathy was assumed to be an infiltrative process with extracellular deposits of amyloid fibrils that cause structural and functional damage to the heart.
The degree of cardiac infiltration does not always correspond to the degree of clinical dysfunction [24] . However, mortality rate directly corresponds to the levels of circulating free amyloidogenic light chains. Their reduction improves survival rates, even though cardiac amyloid deposits remain unaffected [25] [26] [27] .
At the level of the cardiovascular system the AL amyloidosis Recent studies demonstrated that patients with AL cardiomyopathy have an increased expression of stanniocalcin-1 (STC-1) in the heart tissue [33] . This glycoprotein can be induced in vitro in isolated cardiomyocytes in reaction to AL light chains.
Non-amyloidogenic light chains do not cause such reaction [32] .
In mammals, STC-1 is associated with angiogenesis, apoptosis, ischemic damage, inflammation, cell metabolism, differentiation with endothelial permeation, as well as with oxidation stress and impairment of calcium homeostasis. Its pro-apoptotic and anti--apoptotic effect is dependent upon the stimulus and cell type.
STC-1 facilitates cell death as a reaction to various stress signals.
The cardiotoxic effect of STC-1 is mediated by the loss of mitochondrial membrane potential, production of reactive forms of oxygen, increase in the mitochondrial calcium levels accompanied with their decrease in the cytosol [9, 33] . Disrupted calcium levels cause contractility disorder, increased levels of free radicals and mitochondrial dysfunction. The typical cardiac damage in patients with AL amyloidosis is heart failure with normal ejection fraction or infiltrative cardiomyopathy [3] [4] [5] 9 ].
Blood vessels damage
The amyloid often infiltrates vessels thus causing impairment of vasodilatation, that can lead to myocardial ischemia. The intramyocardial vessels are affected in 90% of patients with AL amyloidosis [34] . In rare cases, amyloid deposits in epicardial vessels cause ischemic effects. These deposits are often not revealed by coronary angiography. However, severe vessel obstruction by amyloid is rather rare. On the other hand, an increased incidence of microinfarcts, ischemia and fibrosis contribute to myocardial dysfunction. Cytotoxic effects of amyloid were also demonstrated in blood vessels. Light chains cause endothelial dysfunction related to increased apoptosis of endothelial cells in coronary arteries [35] .
Valvular damage
Even though valves are commonly histologically affected, clinical symptoms and hemodynamic valvular dysfunction are rare findings in amyloidosis [36] . 
Arrhythmias
Amyloid deposits in the heart can be accompanied by fibrosis of the heart's conduction system. Fibrosis, a progressive process, causes abnormalities of conduction, electromechanical dissociation or impairment in automation centers, resulting in fatal arrhythmia [37] . Although all parts of the conduction system can be Thromboembolism AL amyloidosis is associated with an increased risk of atrial thrombosis when compared to other types of amyloidosis.
Thromboembolism can have serious consequences in patients with AL amyloidosis [38] . An intracranial thrombus can be the only early sign of cardiac amyloidosis, although the mechanism of its formation remains unclear. It is predicted that the process is facilitated by amyloid deposits resulting in endocardial, myocardial and endothelial damage, cardiotoxicity as well as hypercoagulation [38] . Patients show a number of similar signs -normal sinus rhythm, normal or slightly decreased left ventricle ejection fraction. Intracardiac thrombi are usually diagnosed in the phase of catastrophic pulmonary or systemic embolism. The prognosis is poor with a survival rate of days to months after the diagnosis [39] .
Pulmonary hypertension and cor pulmonale
In some cases amyloid infiltrates cause marked dilation of the right ventricle in comparison to the left. Such cases are associated with an average survival of 4 months. This condition can be caused by an increased end-diastolic pressure in the left ventricle, or by an increased pulmonary vascular resistance due to amyloid deposition in the pulmonary vasculature. In rare cases, pericardial damage can lead to amyloid infiltration of the lungs with progression to pulmonary hypertension and cor pulmonale [40] . 
